And consolidation in the diagnostics space is only just beginning.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
2019 was an average year for medtech M&A. 2020, not so much.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.